WinstonWınston
Back
America Great Health logo

America Great Health

AAGH
27
Biotechnology · Healthcare
Price
$0.00
-0.00 (-33.33%)
Market Cap
$4.2M
Winston Score
27
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Mixed
Growth
Weak
Cash Flow
Weak
Stability
Data not available
Valuation
Good

Share count rising — dilution

+3.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.44B (2021) → 21.14B (2025)

Winston Score History

The full picture

America Great Health is a small biotechnology company focused on health and wellness products. It sells supplements and related consumer health goods, targeting everyday customers looking for nutritional support. The company operates in the broader healthcare and wellness industry, which is highly competitive and crowded with both large and small players.

The company generates revenue primarily through product sales, likely through direct-to-consumer and online channels. It is a very small company, with a market cap that rounds to essentially zero, meaning it has minimal scale compared to industry peers. The company's operating margin is deeply negative, meaning it spends far more than it earns, which is a serious financial risk — the biggest challenge it faces is reaching a size where revenue can actually cover its costs and sustain the business long-term.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-53.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

YoY Growth Rate

EPS data limited

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

9.5%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$29,346 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

America Great Health's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
86.2%
Premium pricing power — 86.2% gross margin
Profit after running costs
Operating Margin
-282.2%
Losing money on operations — -282.2%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-5.1%
Shrinking sales (-5.1% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
-55%
Weak — only -55% of profit becomes cash
Spare cash per sale
FCF Margin
-97.1%
Burning cash (-97.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
2.0x
Attractive valuation — P/E 2.0

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial